Dipasquale, A., Marinello, A., & Santoro, A. (2021). A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario. J Hepatocell Carcinoma.
Citação norma ChicagoDipasquale, Angelo, Arianna Marinello, e Armando Santoro. "A Comparison of Lenvatinib Versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario." J Hepatocell Carcinoma 2021.
Citação norma MLADipasquale, Angelo, Arianna Marinello, e Armando Santoro. "A Comparison of Lenvatinib Versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario." J Hepatocell Carcinoma 2021.